Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CENTAUR-OLE: AMX0035 in ALS
NCT03488524Phase 2Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS), sponsored by Amylyx Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03488524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488524.